Abstract：
Histiocytoid Sweet\'s syndrome (HSS) is a variant of Sweet\'s syndrome (SS) that clinically resembles SS but differs histologically by infiltrates, predominantly composed of immature cells of the myeloid lineage. Medications such as proteasome inhibitors have been reported to cause HSS but there has been little discussion on the underlying mechanism. Here we report two cases of HSS associated with a proteasome inhibitor. Both patients were on ixazomib for the treatment of multiple myeloma and presented with acute erythematous plaques on the upper half of the body. Pathological findings were consistent with HSS. Similarities between proteasome inhibitor-induced HSS and Nakajo-Nishimura syndrome, an inherited inflammatory disease, can be identified both clinically and histologically, suggesting a potential explanation of the mechanism behind proteasome inhibitor-associated HSS.
摘要：
Sweet综合征（HSS）是Sweet综合征（SS）的一种变体，在临床上类似于SS，但在组织学上因浸润而有所不同。主要由髓系的未成熟细胞组成。据报道，诸如蛋白酶体抑制剂之类的药物会引起HSS，但关于潜在机制的讨论很少。在这里，我们报告了2例与蛋白酶体抑制剂相关的HSS。两名患者均使用ixazomib治疗多发性骨髓瘤，并在上半部出现急性红斑。病理结果与HSS一致。蛋白酶体抑制剂诱导的HSS和Nakajo-Nishimura综合征之间的相似性，遗传性炎症性疾病,可以在临床和组织学上鉴定，提示蛋白酶体抑制剂相关HSS背后机制的潜在解释。
